Emcure Pharmaceuticals Limited
ListedMainboardHealthcare / Pharmaceuticals · NSE / BSE
Emcure Pharmaceuticals Limited, incorporated in 1981, is a leading Indian pharmaceutical company engaged in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products across multiple therapeutic areas. Ranked 13th in domestic sales and 4th in market share in covered markets for MAT September 2023, Emcure is a leader in the gynaecology and HIV antiviral segments. With domestic sales contributing over 50% of total revenue and growing at a CAGR of 10.80% between September 2019 and September 2023, the company has outpaced the Indian pharmaceutical market. It operates five research facilities in India, employing 552 scientists and filing over 1,800 global regulatory documents, including 201 granted patents. Emcure's 13 manufacturing facilities in India produce a wide range of pharmaceutical and biopharmaceutical products, including chiral molecules, iron molecules, and cytotoxic substances. Supported by over 5,000 field personnel and 5,000 stockists across 37 carry-and-forward agents, the company maintains an extensive marketing and distribution network, ensuring strong engagement with healthcare providers and efficient product availability.
Price Band
₹960 – ₹1008
Issue Size
₹1952 Cr
Lot Size
14 shares
GMP
₹300
+29.8%
Est. Listing
₹1308
at current GMP
Subscribed
68.40x
overall
Open
3 Jul 2024
Close
5 Jul 2024
Allotment
8 Jul 2024
Refund
9 Jul 2024
Demat Credit
10 Jul 2024
Listing
10 Jul 2024
Last updated 12 days ago
Overall Subscription
68.40x
Total Demand
QIB Multiplier
191.24x
Institutions & Funds
NII / HNI
49.32x
High Net-Worth
Retail (RII)
7.36x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 3,853,234 | 736,891,932 | 191.24x |
| NIB | 2,889,926 | 142,521,694 | 49.32x |
| HNIs(10L +) | 1,926,618 | 105,770,490 | 54.90x |
| HNIs (2-10L) | 963,308 | 36,751,204 | 38.15x |
| RETAIL | 6,743,160 | 49,605,206 | 7.36x |
| EMPLOYEES | 108,900 | 959,672 | 8.81x |
| Total | 16,485,146 | 1,072,500,198 | 68.40x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| HNIs (10L+) | 9,174 | 100,845 | 10.99x |
| HNIs (2-10L) | 4,587 | 167,799 | 36.58x |
| RETAIL | 481,654 | 2,601,844 | 5.40x |
| Total Applications | 495,415 | 2,870,488 | 5.79x |
Day-Wise Subscription Progress
Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.
About Emcure Pharmaceuticals Limited Public Issue & Market Profile
Emcure Pharmaceuticals Limited is bringing an initial public offering (IPO) in the Healthcare / Pharmaceuticals sector with an aggregate issue size of ₹1,952.03 Crores. The shares are offered at a price band of ₹960 to ₹1008 per equity share on NSE and BSE. Currently, investors are tracking the grey market premium (GMP) and institutional subscription multiples closely across BSE and NSE portals.
Bidding & Quota Instructions:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Allotment Reconciliation Schedule:
Following the close of bidding on 2024-07-05, the basis of allotment is scheduled to be finalized on 2024-07-08. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is Emcure Pharmaceuticals Limited IPO GMP today?
The latest Grey Market Premium (GMP) for Emcure Pharmaceuticals Limited IPO is ₹300 per equity share. Based on the upper price band of ₹960 to ₹1008 per equity share, the estimated listing price is ₹1308 (+29.8% expected listing gain).
What is the expected profit per lot for Emcure Pharmaceuticals Limited IPO?
With a lot size of 14 shares and current GMP of ₹300, the expected profit per application lot is approx ₹4,200 (+29.8% gain). Minimum application cost is approx ₹14,112.
What is the issue size and price band for Emcure Pharmaceuticals Limited IPO?
The Emcure Pharmaceuticals Limited IPO aggregate issue size is ₹1,952.03 Crores with an equity price band set at ₹960 to ₹1008 per equity share. The retail lot size is 14 shares requiring a minimum capital outlay of approx. ₹14,112.
How can I check Emcure Pharmaceuticals Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 68.40x (Retail: 7.36x, QIB: 191.24x, NII: 49.32x). You can track live multiples directly on our dedicated subscription page.
Where and when will Emcure Pharmaceuticals Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Link Intime India Private Limited) and the BSE status verification website on or around 2024-07-08. Investors can verify status using PAN card or application number.
When is the listing date for Emcure Pharmaceuticals Limited IPO?
Emcure Pharmaceuticals Limited shares are scheduled to list on NSE and BSE on 2024-07-10.